Skip to search formSkip to main contentSkip to account menu

enzalutamide

Known as: Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl- 
An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a… 
National Institutes of Health

Related topics

Related topics

6 relations
Androgen Receptor Antagonists [MoA]NCIt Antineoplastic Agent Terminologyenzalutamide 40 MG Oral Capsuleenzalutamide 40 MG Oral Capsule [Xtandi]

Broader (1)

MDV 3100

Narrower (1)

Xtandi

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.
5007 Background: Skeletal fractures, pathological or not, are a frequent and underestimated side-effect of systemic treatment of… 
2019
2019
Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer
Key Points Question How is sipuleucel-T being used to treat patients with advanced prostate cancer, and what are the factors… 
2019
2019
Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression
2019
2019
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.
Review
2016
Review
2016
Targeting the androgen receptor in triple-negative breast cancer.
Review
2015
Review
2015
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian…
Review
2015
Review
2015
The emergence of extracellular vesicles in urology: fertility, cancer, biomarkers and targeted pharmacotherapy
Extracellular vesicles (EV) are small membrane-bound vesicles enriched in a selective repertoire of mRNA, miRNA, proteins and… 
Review
2014
Review
2014
Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
2014
2014
The pluripotency factor Nanog is directly upregulated by the Androgen Receptor in prostate cancer cells
The Androgen Receptor (AR) is a nuclear hormone receptor that functions as a critical oncogene in all stages of prostate cancer… 
2012
2012
Understanding low sugar from NICE-SUGAR.
A 2001 study from a single center in Leuven, Belgium, in which intensive insulin therapy was associated with a relative reduction… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)